Cargando…
Current perspective on rituximab in rheumatic diseases
The steadily increasing knowledge regarding pathogenetic mechanisms in autoimmune rheumatic diseases has paved the way to different therapeutic approaches. In particular, the market entry of biologics has dramatically modified the natural history of rheumatic chronic inflammatory diseases with a mea...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633295/ https://www.ncbi.nlm.nih.gov/pubmed/29042750 http://dx.doi.org/10.2147/DDDT.S139248 |
_version_ | 1783269865149169664 |
---|---|
author | Schioppo, Tommaso Ingegnoli, Francesca |
author_facet | Schioppo, Tommaso Ingegnoli, Francesca |
author_sort | Schioppo, Tommaso |
collection | PubMed |
description | The steadily increasing knowledge regarding pathogenetic mechanisms in autoimmune rheumatic diseases has paved the way to different therapeutic approaches. In particular, the market entry of biologics has dramatically modified the natural history of rheumatic chronic inflammatory diseases with a meaningful impact on patients’ quality of life. Among the wide spectrum of available biological treatments, rituximab (RTX), first used in the treatment of non-Hodgkin’s lymphoma, was later approved for rheumatoid arthritis and anti-neutrophil cytoplasmic antibodies-associated vasculitis. Nowadays, in rheumatology, RTX is also used with off-label indications in patients with systemic sclerosis, Sjögren’s syndrome and systemic lupus erythematosus. RTX is a monoclonal antibody directed to CD20 molecules expressed on the surfaces of pre-B and mature B lymphocytes. It acts by causing apoptosis of these cells with antibody- and complement-dependent cytotoxicity. As inflammatory responses to cell-associated immune complexes are key elements in the pathogenesis of several autoimmune rheumatic diseases, such an approach might be effective in these patients. In fact, RTX, by promoting the rapid and long-term depletion of circulating and lymphoid tissue-associated B cells, leads to a lower recruitment of these effector cells at sites of immune complex deposition, thus reducing inflammation and tissue damage. RTX is of the most interest to rheumatologists as it represents an important additional therapeutic approach. Thus, the advent in clinical practice of approved RTX biosimilars, such as CT-P10, may be of help in improving treatment access as well as in reducing costs. |
format | Online Article Text |
id | pubmed-5633295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56332952017-10-17 Current perspective on rituximab in rheumatic diseases Schioppo, Tommaso Ingegnoli, Francesca Drug Des Devel Ther Review The steadily increasing knowledge regarding pathogenetic mechanisms in autoimmune rheumatic diseases has paved the way to different therapeutic approaches. In particular, the market entry of biologics has dramatically modified the natural history of rheumatic chronic inflammatory diseases with a meaningful impact on patients’ quality of life. Among the wide spectrum of available biological treatments, rituximab (RTX), first used in the treatment of non-Hodgkin’s lymphoma, was later approved for rheumatoid arthritis and anti-neutrophil cytoplasmic antibodies-associated vasculitis. Nowadays, in rheumatology, RTX is also used with off-label indications in patients with systemic sclerosis, Sjögren’s syndrome and systemic lupus erythematosus. RTX is a monoclonal antibody directed to CD20 molecules expressed on the surfaces of pre-B and mature B lymphocytes. It acts by causing apoptosis of these cells with antibody- and complement-dependent cytotoxicity. As inflammatory responses to cell-associated immune complexes are key elements in the pathogenesis of several autoimmune rheumatic diseases, such an approach might be effective in these patients. In fact, RTX, by promoting the rapid and long-term depletion of circulating and lymphoid tissue-associated B cells, leads to a lower recruitment of these effector cells at sites of immune complex deposition, thus reducing inflammation and tissue damage. RTX is of the most interest to rheumatologists as it represents an important additional therapeutic approach. Thus, the advent in clinical practice of approved RTX biosimilars, such as CT-P10, may be of help in improving treatment access as well as in reducing costs. Dove Medical Press 2017-10-03 /pmc/articles/PMC5633295/ /pubmed/29042750 http://dx.doi.org/10.2147/DDDT.S139248 Text en © 2017 Schioppo and Ingegnoli. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Schioppo, Tommaso Ingegnoli, Francesca Current perspective on rituximab in rheumatic diseases |
title | Current perspective on rituximab in rheumatic diseases |
title_full | Current perspective on rituximab in rheumatic diseases |
title_fullStr | Current perspective on rituximab in rheumatic diseases |
title_full_unstemmed | Current perspective on rituximab in rheumatic diseases |
title_short | Current perspective on rituximab in rheumatic diseases |
title_sort | current perspective on rituximab in rheumatic diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633295/ https://www.ncbi.nlm.nih.gov/pubmed/29042750 http://dx.doi.org/10.2147/DDDT.S139248 |
work_keys_str_mv | AT schioppotommaso currentperspectiveonrituximabinrheumaticdiseases AT ingegnolifrancesca currentperspectiveonrituximabinrheumaticdiseases |